Showing 1 - 3 of 3 Items
Showing 1 - 3 of 3 Items
Sort By: Relevance
Journal Article
|Protocol
2023-11-30 • Trials
2023-11-30 • Trials
BACKGROUND
Treatment for fluoroquinolone-resistant multidrug-resistant/rifampicin-resistant tuberculosis (pre-XDR TB) often lasts longer than treatment for less resistant strains, yi...
Treatment for fluoroquinolone-resistant multidrug-resistant/rifampicin-resistant tuberculosis (pre-XDR TB) often lasts longer than treatment for less resistant strains, yi...
Journal Article
|Research
2017-07-01 • Lancet Infectious Diseases
2017-07-01 • Lancet Infectious Diseases
BACKGROUND
The UK introduced 4CMenB-a multicomponent vaccine against serogroup B meningococcal disease-into the national infant immunisation programme in September, 2015. The Meningo...
The UK introduced 4CMenB-a multicomponent vaccine against serogroup B meningococcal disease-into the national infant immunisation programme in September, 2015. The Meningo...
Journal Article
|Protocol
2021-09-25 • Trials
2021-09-25 • Trials
BACKGROUND
Treatment of multidrug- and rifampin-resistant tuberculosis (MDR/RR-TB) is expensive, labour-intensive, and associated with substantial adverse events and poor outcomes. W...
Treatment of multidrug- and rifampin-resistant tuberculosis (MDR/RR-TB) is expensive, labour-intensive, and associated with substantial adverse events and poor outcomes. W...